The widening spectrum of infectious neurological disease by Kennedy, Peter GE
Journal of Neurology, Neurosurgery, and Psychiatry 1990;53:629-632
Editorial
The widening spectrum of infectious neurological disease*
Three important areas of study reflect the widening range
of neurological infections. These are (a) new technologies
for pathogenetic studies and diagnosis, (b) the increasing
range of neural pathogens and (c) new therapeutic tools.
(a) New technologies for pathogenesis studies and
diagnosis of neurological disease
Until relatively recently most physicians specialising in
infectious diseases relied largely on clinical bedside diag-
nosis and this is still of critical importance in, for example,
many childhood infectious diseases such as chickenpox,
measles and mumps, all of which have neurological
sequelae. The development of modem investigative tech-
niques can now supplement the classical methods of viral
and bacterial isolation from body fluids and measurement
of antiviral antibodies.
There are numerous problems when attempting to
assign a particular virus to a neurological condition. When
a virus is isolated from a patient during such an illness it
may be the result of a co-existing and unrelated virus
infection. The virus may not be isolated from the
neurological or other site or there may be chronic asymp-
tomatic secretion of virus. Moreover, serological studies
may be misleading in that there may be non-specific
polyclonal activation of virus as part of a generalised
immune response to infection. There may also be persis-
tent viral antibody levels from a previous infection. Virus
isolation or antibody rises may also represent viral reactiva-
tion and not a primary infection. Other problems with
serological viral diagnosis include: inadequate sensitivity,
inadequate specificity (for example, unwanted cross-reac-
tions), the fact that antibody elevations may be transient, as
well as practical difficulties with the collection and timing
of specimens.'
Some of the more important new technologies available
for viral and bacterial diagnosis will now be considered.
(i) Molecular analysis of viral and bacterial isolates
Molecular analysis of viral and bacterial isolates obtained
from patients has proved to be very useful both in diagnosis
and pathogenetic studies. For example, genetic analysis of
herpes simplex virus (HSV) isolates using restriction
enzyme techniques and methods for analysing polypeptide
profiles have shown that HSV-1 isolates from human
ganglia (trigeminal, superior cervical and vagus) are gen-
erally specific for individuals in that they can usually be
distinguished from one another.2
Similar techniques have also been used to show that
HSV encephalitis may be due to various types of HSV
infection including primary infection, reactivation ofHSV
which had remained latent in sensory ganglia, or reinfec-
tion with a second virus strain.3 Genetic analysis has helped
to clarify the molecular determinants of neurovirulence in
poliovirus vaccine strains. As live attenuated poliovirus
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passes through the infant. gut it becomes increasingly
neurotropic and this has been shown to be associated with a
single nucleotide change in the genome.4 Molecular
analysis of bacterial components has also proved useful in
understanding the pathogenesis of bacterial meningitisincluding bacterial neurovirulence.5
(ii) Identification of antigens in body fluids and tissues
Increasingly sophisticated antigen detection methods
including the use of monoclonal antibodies are proving
useful diagnostic aids in both viral and bacterial infections
of the CNS. For example, enzyme-linked immunosorbent
assays (ELISA) have been used extensively to detect a
variety of microbial antigens and have proved to be
particularly useful in the differentiation ofvarious causes of
meningitis.' This technique has also proved to be useful in
the diagnosis of human immunodeficiency virus (HIV)infection, although the technique of Western blotting
whereby antigens are detected on electrophoretic gels using
specific antibodies, provides a standard confirmatory test
for this infection.
Immunofluorescence has been used for a number of
years in a variety of neurological conditions. While this
technique is often only semi-quantitative, it has been
particularly useful in the diagnosis of varicella-zoster virus(VZV) infections using the indirect membrane
immunofluorescent assay which appears to be capable of
distinguishing cases of varicella or herpes zoster with
clinical CNS involvement from those individuals with
VZV infections without neurological involvement.6
The technique of double-labelling immunofluorescence
whereby two different antigens can be visualised in tissue
culture or tissues simultaneously using antibodies con-jugated to two different fluorochromes has been par-
ticularly useful, especially in pathogenetic studies.7 Using
this technique the differential susceptibility of neural cells
to virus infection can be determined by localising viral
proteins in marker-identified neural cell types.78 Immuno-
fluorescence studies have also been ofvalue in the diagnosis
of herpes simplex encephalitis,9 although a rapid test for
this condition is still urgently required.
Antigen detection by the horseradish peroxidase
technique is more sensitive than immunofluorescence andis ofconsiderable value in both diagnostic and pathogenetic
studies. The avidin-biotin peroxidase technique is curren-
tly the most sensitive of these antigen detection methods.
Peroxidase techniques have the advantage of enabling a
permanent histological preparation to be made.'0
(iii) Nucleic acid detection in body fluids and tissues
The development of increasingly sensitive molecular tech-
niques such as Southern-blot hybridisation, dot-blot
hybridisation and in situ hybridisation (ISH) for localising
viral genomes in pathological tissues has been of the
greatest importance in understanding the basis of virally-induced neurological disease." Radiolabelled nucleic acid(DNA or RNA) probes are used in autoradiographic
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procedures which visualise specific hybridisation between
the probes and nucleic acid sequences in the cell or tissue
specimens under test. ISH has the advantage of being able
to localise the viral genome within individual cells and is
particularly useful in detecting a small amount of virus
which is unevenly distributed within a tissue. These
techniques have been used, for example, to demonstrate
HIV in the brains ofpatients with HIV encephalitis,'2 HSV
nucleic acid in patients with HSV encephalitis9 and in
latently infected sensory ganglia,'3 and measles virus gen-
ome in some patients with multiple sclerosis."4
These techniques are also being employed in a number of
laboratories to investigate the possible viral aetiology of
other chronic neurological diseases such as motor neuron
disease"5 and Alzheimer's disease.'6 ISH can also be
combined with immunocytochemistry to co-localise viral
proteins or cell markers and nucleic acids within the same
cell as has been demonstrated in the case of the visna
retrovirus of sheep.'7 Visna virus RNA has been localised
within marker-identified oligodendrocytes in the brain of a
sheep with encephalitis.8 19 Class II antigens and nucleic
acids have also been co-localised in macrophages in this
disease.'7 This double-labelling technique has also been of
considerable value in recent pathogenesis studies of HSV
encephalitis on human brain biopsies.9
Nucleic acid detection has recently been revolutionised
by the polymerase chain reaction (PCR) in which con-
siderable amplification of nucleic acids in cells and/or
tissues is possible.20 The sensitivity of this technique is
exceptionally high with the ability to detect a single viral
genome in a cell culture or tissue specimen containing
many thousands of cells. Although care must be taken to
exclude the possibility of contamination, PCR is already
proving to be an exceptionally valuable technique for both
diagnosis and pathogenetic studies. For example, it has
been used to demonstrate HIV in patients' lymphocytes
before the HIV antibody is detectable and thus is of use in
early diagnosis.2' PCR may also clarify questions concern-
ing acute versus chronic virus infections of the nervous
system in that some neurological diseases may be due to
chronic viral infection which can only be detected using
such a very sensitive technique. Such an approach should
be particularly useful in investigating cases ofthe post-viral
fatigue syndrome and motor neuron disease.
(iv) Viral reassortants and recombinants
Although viral reassortant and recombinant techniques are
not in routine use for ordinary diagnosis, they are men-
tioned here since they have been so valuable in studies of
pathogenesis. For example, intertypic recombinant viruses
between HSV-1 and HSV-2 strains have been used to show
that a small region of the HSV-1 genome has an important
role in determining the ability of the virus to spread to and
replicate in the CNS.22
Although the mammalian reoviruses are not ofparticular
importance in human disease, Fields et al have used the
mouse reovirus model highly effectively to study the
genetic determinants of neurovirulence and neurotrop-
ism.23 Viral reassortants were constructed using segments
of the genome from three different types of reovirus. These
different serotypes differ in their capacity to infect neural
cells and spread within the nervous system. The three main
reovirus serotypes all contain segmental double-stranded
RNA, but type 1 has an affinity for ependymal cells
whereas type 3 infects neurons preferentially.23 Type 3 also
results in fatal encephalitis in neonatal mice. Using the
intertypic reassortant viruses it was shown that the S 1 gene,
which encodes the viral cell attachment protein (Sigma 1),
determines whether the virus infects ependymal cells or
neurons24 and also whether it spreads along nervous
pathways or by haematogenous routes.25
(v) New brain imaging techniques
The relatively recent development of sophisticated
neuroimaging techniques has played an important role in
both disease diagnosis and increasing our understanding of
pathogenesis. For example, computed tomography (CT)
scanning has clarified some aspects of the natural history of
tuberculous meningitis. It has shown, for example, that the
incidence of tuberculoma of the nervous system is much
greater than had previously been thought during the course
oftuberculous meningitis and that many ofthese lesions do
not produce symptoms.26 CT scanning has been par-
ticularly useful in the diagnosis and management of
patients with neurocysticercosis. A variety ofabnormalities
can be identified by CT scanning including parenchymal
cysts, hydrocephalus, areas of calcification and vasculitic
infarction.27 Studies using contrast enhancement can also
provide specialised information which is particularly
useful for monitoring therapy. Moreover, the absence of
cerebral oedema, as assessed by CT scanning in patients
with cerebral malaria, has directly resulted in modification
of therapy in that it has obviated the need for dexameth-
asone therapy in this condition.28
Magnetic resonance imaging (MRI) has already proved
to be of great value in a variety of infectious neurological
diseases. It has been particularly useful in detecting
demyelinating lesions in HIV encephalitis29 and through its
ability to detect white matter lesions with some precision it
can also be used for the non-invasive diagnosis of such
conditions as progressive multifocal leucoencephalopathy
and post-infectious encephalomyelitis.29 A more recent
development is single photon emission computerised
tomography (SPECT) scanning in which abnormalities of
blood flow have been demonstrated in both herpes simplex
encephalitis and non-herpetic encephalitis.?'
(b) The widening range of neural pathogens
Clinicians have recognised for some time that a wide
variety of infectious agents can produce neurological
disease. However, over the last decade the range of
neurotropic viruses and bacteria has appeared to widen.
This includes an increasing range of familiar pathogens as
well as the recognition of new pathogens.
There are a number of examples of the first category.
Immunosuppressive therapy for malignancy and other
conditions with cytotoxic and other drugs has been
increasingly effective in recent years. Unfortunately, one of
the consequences of this increased therapeutic immun-
osuppression is an increase in the frequency and range of
fungal infections (for example, Candidiasis), viral infec-
tions (for example, progressive multifocal leucoence-
phalopathy (PML) due to the JC papovavirus29) and
bacterial infections (for example Listeria monocytogenes) in
renal transplant patients.
In some cases there has been a change in the host
response to familiar organisms which produce opportunis-
tic infections. The increased range of a species within
known pathogenic groups causing disease is well illustrated
by spirochaetal infections. For example, while the spiro-
chaete Treponema pallidum has been recognised for many
years as being the cause of syphilis, the spirochaete Borrelia
burgdorferi, which causes Lyme disease, was first recogn-
ised in 1975 in Connecticut, United States.3' Lyme disease,
which is tick-borne, may well have been around somewhat
earlier than this and the apparent increasing incidence of
this disease at present is due, at least in part, to the fact that
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clinicians are actively seeking evidence of B burgdorferi
infection where clinically relevant. A variety of
neurological symptoms and signs occur in about 15% of
cases when the nervous system is involved in the second
stage of the disease.32 This includes meningoencephalitis,
cranial nerve palsies and radiculopathy.32
Another relatively recently recognised disease is legion-
naires' disease caused by the bacterium Legionella pneumo-
phila, which is also known to produce diverse neurological
impairment.33 Interestingly, legionnaires' disease was
prevalent as long ago as the 1940s and 1950s, as shown by
retrospective studies,3435 and may well have been the actual
cause of some cases of so-called "virus pneumonia".
There are many causes of so-called "new" diseases. An
environmental change such as the introduction ofa toxin or
irradiation may occur and be manifested in a variety of
ways. There may also be a change in the host response to
familiar pathogens as occurs frequently in immunosup-
pressed individuals. A further mechanism is through a
pathogen "jumping" species as may well have occurred in
the case of HIV. Moreover, a pathogen may be identified
by a new technology as in the case of legionnaires' disease
and PML. A hypothetical possibility is that a pathogen may
be externally introduced either from extraterrestrial sour-
ces or through genetic engineering. For practical purposes
the only genuinely new recent infectious disease is HIV.
However, these various possibilities are not mutually
exclusive, for example, for a pathogen to "jump" species
thereby extending its own specificity there may well have to
be a concomitant change in the properties of the virus itself
as well as the host response.
Infection with human immunodeficiency virus (HIV)
has now reached epidemic proportions and is emerging as
the most serious public health problem that infectious
disease physicians and others have to deal with.
Neurological complications are a very significant feature of
HIV infection at all stages ranging from HIV seropositivity
through to AIDS-related complex (ARC) and the full-
blown AIDS syndrome. These various complications have
been reviewed in detail.3637 About 10% of patients with
HIV infection present neurologically,3839 whilst approx-
imately 70% of patients with AIDS have some evidence of
neurological involvement and this figure may extend to
around 80% if pathological data are also taken into
consideration.36 The complications include a wide variety
ofinfections including those caused by HIV itselfand other
viruses, fungi (especially candida and cryptococcus), bac-
teria and protozoa (toxoplasmosis) as well as tumours ofthe
nervous system which are usually primary or systemic
lymphomas;3' Cerebrovascular complications and a wide
variety ofperipheral nerve disorders including sensory and
motor neuropathies of both axonal and demyelinating type
are also well-recognised."
Probably the most important of these complications is an
HIV encephalitis, also known as the AIDS-dementia
complex, which is caused by direct HIV infection within
the brain.'2 However, the precise pathogenesis of the brain
lesions has not been clarified and although HIV has been
demonstrated within macrophages, multinucleate giant
cells and probably endothelial cells using molecular tech-
niques41 its localisation within glial cells (astrocytes and
oligodendrocytes) and neurons has not been demonstrated
convincingly. It is likely that indirect mechanisms are
important, for example, the release of lymphokines, and
simultaneous infection with HIV and other opportunistic
viruses may play an important role.42 Whether the success-
ful introduction of public health measures aimed at halting
spread ofthe disease will be successful is unclear at present.
It is clear, however, that HIV infection will be a major
problem for some time to come and that neurological
features will continue to be prominent.
(c) New therapeutic tools
These include well-recognised therapy for newly recogn-
ised diseases, newly developed therapy for well-recognised
diseases, and newly developed therapy for new diseases.
Well-recognised therapy has been effective for newly
recognised diseases, including established antibiotics such
as penicillin in Lyme disease. Another example is the use
of erythromycin in patients suffering from legionnaires'
disease.
In considering the role of newly developed therapies for
well-recognised diseases, it is worth considering that what
is new therapeutically today may seem very old-fashioned
if not barbaric in the future. Over a 100 years ago Sir
William Gowers in his classic textbook on diseases of the
nervous system43 mentions a variety of somewhat disturb-
ing treatments for meningitis. For example, leeching and
local application of mercury along the spine were recom-
mended and some of the treatments sound worse than the
disease! Almost 20 years later we learn from the Medical
Annual under "New Treatments" that oral Creosote is an
effective treatment for tuberculous meningitis." Neverthe-
less, there have been some recent advances which have
produced truly outstanding results. Prominent is the use of
the nucleoside analogue acylovir for patients with herpes
simplex encephalitis. Intravenous administration of this
drug given early can drastically reduce both the mortality
and morbidity of this condition which is the commonest
cause of fatal sporadic encephalitis occurring in humans.45
The use of the helminthicide drug praziquantel has proved
to be remarkably effective in treating neurocysticercosis
and is likely to have a very significant impact on this disease
in developing countries.27
If a disease is genuinely new, it may well be necessary to
develop completely new therapy unless one is particularly
fortunate in having to hand established therapies which
might prove effective. An example ofsuch newly developed
therapy is the drug azidothymidine which has a definite
effect on the systemic complications ofHIV infection' and
in preliminary studies the AIDS-dementia complex and
other neurological conditions also appear to respond
favourably to this drug.47 In view of the theoretical and
practical difficulties in developing a vaccine for AIDS the
role ofchemotherapy and immunotherapy is likely to be of
considerable importance. The existence of HIV variants
which may have different properties and sensitivities to
drugs must also be taken into consideration.
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